Firm said the five-year partnership with the UK’s Vaccines Manufacturing and Innovation Centre (VMIC) would also help it make other viral vector vaccines.
Gene and cell therapy firm Oxford Biomedica said on Monday it signed a new manufacturing agreement to help it scale up production of AstraZeneca’s potential COVID-19 vaccine to cater to demand in the United Kingdom and Europe.
Oxford Biomedica, which last week appointed a new chair as it vies for a bigger role in vaccine manufacturing, said the five-year partnership with the UK’s Vaccines Manufacturing and Innovation Centre (VMIC) would also help it make other viral vector vaccines.
Comments
Comments are closed for this article.